Sydney Lupkin

Spoiler: There are some decreases this year, too. Here’s an overview of the changing prices and what to make of them.

January is when drug makers typically hike their prices. This year, there’s a mixed bag of price increases and a few notable declines, such as on some forms of insulin.

Shortages of drugs ranging from life-saving chemotherapies to basic generics are straining the health care system. Hospitals are adapting to chronic interruptions in the supply of medicines.

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here’s what really went down.

Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that’s not enough help.

The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.

Moderna said people without insurance will be able to get its COVID vaccine at no cost after the U.S. government bows out. But patients will have to use the company’s cumbersome assistance program.

An insulin maker is cutting its prices. Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes.

Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.